Stock Forecast

  CureVac N.V. ( CVAC) Stock. Should you Buy or Sell?    $ 9.68

0.00 (0.00 %)



CureVac N.V. Analysis

Updated on 10-09-2022
Symbol CVAC
Price $9.68
Beta 2.952
Volume Avg. $528.82 thousand
Market Cap $1.81 B
52 Week Range $9.35 - $67.96


CureVac N.V. opened the day at $9.68 which is 0.00 % on yesterday's close. CureVac N.V. has a 52 week high of $67.96 and 52 week low of $9.35, which is a difference of $58.61. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $1.81 B and total net profit is $102990000 which means the company is trading at 17.62 times profit to market capitalization. Theoretically, if you were to buy CureVac N.V. for $1.81 B, it would take 15 years to get your money back. CureVac N.V. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.



Price Chart


1 D | All


Financials




CureVac N.V. Stock Forecast - Is CureVac N.V. a Buy or Sell?


DCF ScoreStrong Buy
ROE ScoreNeutral
ROA ScoreNeutral
DE ScoreNeutral
PE ScoreStrong Sell
PB ScoreStrong Buy
Overall RecommendationBuy

Growth and Value


PE Ratio -6.928
Dividend Yiel 0.000
Net Profit Margin -1.900


Valuing CureVac N.V.


Price Book Value Ratio 2.430 Price To Book Ratio 2.430
Price To Sales Ratio 13.161 Price Earnings Ratio -6.928


How liquid is CureVac N.V.


Current Ratio 3.453
Quick Ratio 3.018


Debt


Debt Ratio 0.327 Debt Equity Ratio 0.486
Long Term Debt To Capitalization 0.055 Total Debt To Capitalization 0.061



Latest news about CureVac N.V.


Here's Why CureVac N.V. (CVAC) is Poised for a Turnaround After Losing 20.9% in 4 Weeks

CureVac N.V. (CVAC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.

Date : 29/08/2022

BioNTech, Pfizer sue CureVac in U.S. over COVID-19 vaccine patent claims

COVID-19 vaccine maker BioNTech said on Tuesday that it and partner Pfizer have filed a complaint with the U.S. District Court in Massachusetts, seeking a judgment that they did not infringe U.S. patents held by rival CureVac.

Date : 26/07/2022

Wall Street Analysts Predict a 96% Upside in CureVac N.V. (CVAC): Here's What You Should Know

The mean of analysts' price targets for CureVac N.V. (CVAC) points to a 96.4% upside in the stock.

Date : 11/07/2022

BioNTech sued by CureVac over its mRNA technology

CureVac (NASDAQ:CVAC) has filed a patent lawsuit in Germany against BioNTech (NASDAQ:BNTX) in what is one of the first court cases in which a company has sued another for using mRNA technology in developing a coronavirus vaccine. According to Germany-based CureVac, it will "assert its intellectual property rights, accumulated over more than two decades of pioneering work in mRNA technology, which contributed to Covid-19 vaccine development", and is seeking "fair compensation" from BioNTech and two subsidiaries.

Date : 06/07/2022

CureVac Files COVID-19 Vaccine Patent Infringement Lawsuit Against BioNTech

CureVac N.V. (NASDAQ: CVAC) has moved to assert its intellectual property rights, accumulated over two decades of pioneering work in mRNA technology, which contributed to COVID-19 vaccine development.

Date : 05/07/2022





About CureVac N.V.


CEO : Dr. Franz-Werner Haas L.L.M., LLD, Ph.D., LL.M.
Sector : Healthcare
Industry : Biotechnology

Website : https://www.curevac.com

Exchange : NASDAQ Global Market

Description :

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.


My Newsletter

Sign Up For Updates & Newsletters